Company: NIVFW
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001213900-25-033966
Chunk: 81

Company: NewGenIvf Group Ltd
Filing Date: 2025-04-22
Form: 20-F
Item: Item 5
Chunk 81
---
 other income (expenses), net                                                                                199,688          66,176  
  (Loss) Income before taxes                                                                                       (960,807         108,418  
  Tax income (expense)                                                                                              486,706               —  
  Net (loss) income                                                                                                (474,101         108,418  
  Less: net income attributable to non-controlling interests                                                         50,542         (21,775  
  Net (loss) income attributable to the shareholders of the Company                                                (524,643         130,193  
  Other comprehensive (loss) income                                                                                                          
  Foreign currency translation adjustment                                                                            32,529         (22,704  
  Total comprehensive (loss) income                                                                                (441,572          85,714  
  Less: Total comprehensive (loss) income attributable to non-controlling interests                                  56,908         (27,621  
  Total comprehensive (loss) income attributable to the shareholders of the Company                                (498,480         113,335  
  Earnings per share – basic                                                                                          (1.32            3.53  
  – diluted                                                                                                           (0.64            3.53  
  Weighted average shares outstanding * – basic                                                                     358,108          30,757  
  - diluted                                                                                                         743,323          30,757  

  Subsequent to 2024 year end, the Company carried out a 1-for-20 reverse                                                                     
  stock split of its issued and unissued shares which was effected on February 11, 2025. The shares above have been adjusted retrospectively  
  for this reverse stock split.                                                                                                               
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Year Ended December 31, 2024 Compared with Year Ended December 31,
2023

Revenue

NewGenIvf’s revenue
increased by approximately 5.8% from US$5,136,153 in 2023 to US$5,433,375 in 2024.

IVF treatment services

NewGenIvf’s IVF treatment
service revenue increased by approximately 35.1% from US$4,021,696 in 2023 to 5,433,375 in 2024. This increase was primarily the result
of our continued expansion of clinics in Thailand and clinic in Kyrgyzstan focusing on IVF services.

Surrogacy and ancillary caring services

New